{
    "clinical_study": {
        "@rank": "100969", 
        "arm_group": [
            {
                "arm_group_label": "Failed group", 
                "arm_group_type": "Experimental", 
                "description": "Patients who have recurrence of menstruation after changing endocrine therapy to anastrozole and then go back to the original SERMs therapy."
            }, 
            {
                "arm_group_label": "Succeeded group", 
                "arm_group_type": "Experimental", 
                "description": "Patients who have no recurrence of menstruation after changing endocrine therapy and then go on with anastrozole therapy."
            }, 
            {
                "arm_group_label": "No chang group", 
                "arm_group_type": "Active Comparator", 
                "description": "Patients who don't change the endocrine therapy and go on with the original tamoxifen or toremifene therapy."
            }
        ], 
        "brief_summary": {
            "textblock": "It suggests in the Guideline that the postmenopausal women with breast cancer who have taken\n      selective estrogen receptor modulators (SERMs) therapy for 2-3 years could benefit from\n      changing endocrine therapy to aromatase inhibitors (AIs). This is a prospective, randomized\n      and non-inferior trial to evaluate the prognosis of changing endocrine therapy from SERMs to\n      AIs in perimenopausal and recently postmenopausal women with early-stage hormone\n      receptor-positive breast cancer."
        }, 
        "brief_title": "Prognostic Evaluation of Changing Endocrine Therapy in Women With Breast Cancer", 
        "condition": "Breast Cancer", 
        "condition_browse": {
            "mesh_term": "Breast Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Written informed consent must be obtained and documented according to the local\n             regulatory requirements prior to beginning specific protocol procedures.\n\n          -  Age of at least 45 and at most 55 years.\n\n          -  Performance status (Karnofsky-Index) \uff1e80%\n\n          -  Steroid receptor (estrogen and progesterone) positive tumor (diagnosis according to\n             hospital standard-procedures).\n\n          -  No clinical evidence of local recurrence or distant metastases.\n\n          -  Complete staging work-up within 3 months prior to registration. All patients must\n             have (bilateral) mammography or breast MRI, chest X-ray; other tests may be performed\n             as clinically indicated.\n\n          -  Patients have taken the SERMs as endocrine therapy for 2-4 years.\n\n          -  Patients who have had amenorrhea for at least half a year.\n\n          -  Life expectancy of at least 10 years, disregarding the diagnosis of cancer.\n\n          -  Adequate organ function including normal red and white blood count, platelets, serum\n             creatinine, bilirubin, and transaminases within normal range of the institution.\n\n          -  Patients must be available for and compliant to treatment and follow-up.\n\n          -  Patients registered on this trial must be treated and followed up at the\n             participating center.\n\n        Exclusion Criteria:\n\n          -  Known hypersensitivity reaction to the investigational compounds or incorporated\n             substances.\n\n          -  Hormone receptor-negative breast cancer.\n\n          -  Local recurrence and/or metastasis of breast cancer.\n\n          -  History of hysterectomy.\n\n          -  Pregnant or lactating patients. Patients of childbearing potential must have a\n             negative pregnancy test (urine or serum) within 14 days prior to registration.\n\n          -  History of osteoporosis and/or fractures due to osteoporosis.\n\n          -  Prior or concomitant secondary malignancy (except non-melanomatous skin cancer or\n             carcinoma in situ of the uterine cervix)\n\n          -  Any other serious medical pathology, such as congestive heart failure; unstable\n             angina; history of myocardial infarction during the previous year; uncontrolled high\n             risk arrhythmias\n\n          -  Other serious illness or medical condition that may interfere with the understanding\n             and giving of informed consent and the conduct of the study.\n\n          -  Concurrent treatment with other experimental drugs or any other anti-cancer therapy.\n\n          -  Males."
            }, 
            "gender": "Female", 
            "healthy_volunteers": "No", 
            "maximum_age": "55 Years", 
            "minimum_age": "45 Years"
        }, 
        "enrollment": {
            "#text": "600", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "March 19, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02097459", 
            "org_study_id": "PUMCH-BREAST-AI"
        }, 
        "intervention": [
            {
                "arm_group_label": [
                    "Failed group", 
                    "Succeeded group"
                ], 
                "intervention_name": "Anastrozole", 
                "intervention_type": "Drug", 
                "other_name": "Arimidex"
            }, 
            {
                "arm_group_label": [
                    "Failed group", 
                    "No chang group"
                ], 
                "intervention_name": "Tamoxifen", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": [
                    "Failed group", 
                    "No chang group"
                ], 
                "intervention_name": "Toremifene", 
                "intervention_type": "Drug", 
                "other_name": [
                    "Fareston", 
                    "Shu Rui"
                ]
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Tamoxifen", 
                "Toremifene", 
                "Anastrozole"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": [
            "Breast cancer", 
            "Endocrine therapy", 
            "Perimenopausal and recently postmenopausal patients", 
            "Early-stage hormone receptor-positive"
        ], 
        "lastchanged_date": "March 24, 2014", 
        "location": {
            "facility": {
                "address": {
                    "city": "Beijing", 
                    "country": "China", 
                    "zip": "100730"
                }, 
                "name": "Peking Union Medical College Hospital"
            }
        }, 
        "location_countries": {
            "country": "China"
        }, 
        "number_of_arms": "3", 
        "official_title": "Prognostic Evaluation of Changing Endocrine Therapy in Perimenopausal and Recently Postmenopausal Women With Early-stage Hormone Receptor-Positive Breast Cancer", 
        "other_outcome": [
            {
                "measure": "Disease Free Survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "3 years"
            }
        ], 
        "overall_official": {
            "affiliation": "Peking Union Medical College Hospital", 
            "last_name": "Qiang Sun, Doctor", 
            "role": "Study Chair"
        }, 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "China: Ministry of Health", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 3", 
        "primary_completion_date": {
            "#text": "March 2024", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Disease free survival", 
                "safety_issue": "No", 
                "time_frame": "10 years"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "10 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02097459"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Peking Union Medical College Hospital", 
            "investigator_full_name": "Qiang SUN", 
            "investigator_title": "Chief of Breast Surgery Department, Professor", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "measure": "Disease Free Survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }, 
            {
                "measure": "Overall Survival", 
                "safety_issue": "No", 
                "time_frame": "5 years"
            }
        ], 
        "source": "Peking Union Medical College Hospital", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Peking Union Medical College Hospital", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2014", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "March 2014"
    }
}